Roche & Quest Establish Toeholds in Emerging Alzheimer’s Blood Testing Market
While Roche has an early lead, Quest recently made key moves to improve its position in the AD patient-initiated blood testing market.
Already a member? Log in here
Can Ophthalmic Biomarkers Offer Insights into Brain Pathologies?
Protein levels in the vitreous humor may have the potential to support the diagnosis and staging of neurodegenerative diseases.
Already a member? Log in here
Easier, Noninvasive Diagnosis of Neurological Disorders
More companies have begun offering neurofilament light chain blood tests as a cost-effective alternative to conventional methods.
Already a member? Log in here
Roche Alzheimer’s Early Detection Tests Get FDA Green Light
In this month’s diagnostics pipeline report, Roche gets clearance for two new Alzheimer’s early detection tests.
Already a member? Log in here
Which Blood Tests Are Best at Early Alzheimer’s Detection?
A recent study led by a team at the University of Gothenburg shows that multiple biomarkers could ID the disease even in people with no symptoms.